Clinical Trial Update: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia [Phase 3]

View source ↗

Summary

This update outlines the ongoing pivotal open-label Phase 3 trial of QTX-2101 in adults with acute promyelocytic leukemia. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• QTX-2101

Snippet

Sponsor: Quetzal Therapeutics | Conditions: Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Status: RECRUITING